Latest Desert Gateway Inc. (RTRX) Headlines
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Retrophin (RTRX) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:46AM CST
Retrophin was a big mover last session, with shares rising over 14%.
5 Stocks Rising on Unusual Volume
at The Street - Wed Feb 19, 5:30AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 14, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:46AM CST
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.
Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:04AM CST
Retrophin, Inc. was a big mover last session, as the company saw its shares rise by nearly 50% on the day.
Retrophin Shares Boom Following Manchester Pharma Buyout
Ben Fidler, The Motley Fool - Motley Fool - Thu Feb 13, 5:30PM CST
Shares of Retrophin on Thursday soared after the company cut a deal to acquire privately held Manchester Pharmaceuticals and, along with it, a drug that's long been prescribed off-label for a rare inherited disease. Late Wednesday, New...
Why Retrophin, Orbitz Worldwide, and Skechers Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The broad-based S&P 500 started the trading day off a...
Why Retrophin Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 12:27PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Retrophin , a clinical-stage...
Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals
Business Wire - Wed Feb 12, 5:11PM CST
--Management to Host Conference Call and Webcast Tomorrow at 8:30 a.m. ET
Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?
Amy Ho, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
Duchenne's muscular dystrophy is a debilitating disease of young males resulting from an early stop sign (nonsense mutation) in an essential muscle protein dystrophin. While only 35,000 patients in the US and Europe are afflicted, the disease is so...
Retrophin to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 8:00AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that Founder and CEO Martin Shkreli will present a corporate overview and update at the 16th Annual BIO CEO & Investor Conference being held February 10-11 in New York City.
Can The Uptrend Continue for Retrophin (RTRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 5:53AM CST
Can The Uptrend Continue for Retrophin (RTRX)?
Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit
PR Newswire - Mon Jan 13, 5:30PM CST
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced the dismissal of the derivative lawsuit by the Court of Chancery of the State of Delaware. The derivative lawsuit was filed on October 24, 2013, by a shareholder, Retrophin Inc., against the Transcept Board of Directors, purporting to assert claims on behalf of Transcept, alleging that our Board of Directors approved and paid excessive compensation to our directors.
'Mad Money' Lightning Round: Zynga Can Go Higher
at The Street - Sat Mar 08, 5:00AM CST
Cramer is staying away from Solazyme but thinks Retrophin is too frothy.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 07, 7:17PM CST
Cramer will be watching a number of conferences for a read on the economy.
Biotech Sector Performance February 2014: Red Hot But...
at The Street - Sat Mar 01, 11:01AM CST
An epic month of biotech stock performance ends with a significant sell off.
Retrophin (RTRX) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:46AM CST
Retrophin was a big mover last session, with shares rising over 14%.
5 Stocks Rising on Unusual Volume
at The Street - Wed Feb 19, 5:30AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 14, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:46AM CST
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.
Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:04AM CST
Retrophin, Inc. was a big mover last session, as the company saw its shares rise by nearly 50% on the day.
Retrophin Shares Boom Following Manchester Pharma Buyout
Ben Fidler, The Motley Fool - Motley Fool - Thu Feb 13, 5:30PM CST
Shares of Retrophin on Thursday soared after the company cut a deal to acquire privately held Manchester Pharmaceuticals and, along with it, a drug that's long been prescribed off-label for a rare inherited disease. Late Wednesday, New...
Why Retrophin, Orbitz Worldwide, and Skechers Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The broad-based S&P 500 started the trading day off a...
Why Retrophin Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 13, 12:27PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Retrophin , a clinical-stage...
Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals
Business Wire - Wed Feb 12, 5:11PM CST
--Management to Host Conference Call and Webcast Tomorrow at 8:30 a.m. ET
Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?
Amy Ho, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
Duchenne's muscular dystrophy is a debilitating disease of young males resulting from an early stop sign (nonsense mutation) in an essential muscle protein dystrophin. While only 35,000 patients in the US and Europe are afflicted, the disease is so...
Retrophin to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 8:00AM CST
Retrophin, Inc. (NASDAQ:RTRX) today announced that Founder and CEO Martin Shkreli will present a corporate overview and update at the 16th Annual BIO CEO & Investor Conference being held February 10-11 in New York City.
Can The Uptrend Continue for Retrophin (RTRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 5:53AM CST
Can The Uptrend Continue for Retrophin (RTRX)?
Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit
PR Newswire - Mon Jan 13, 5:30PM CST
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced the dismissal of the derivative lawsuit by the Court of Chancery of the State of Delaware. The derivative lawsuit was filed on October 24, 2013, by a shareholder, Retrophin Inc., against the Transcept Board of Directors, purporting to assert claims on behalf of Transcept, alleging that our Board of Directors approved and paid excessive compensation to our directors.
